.jpg "Intercept Pharma (NASDAQ: ICPT)")
In a report released yesterday, Jay Olson from Oppenheimer maintained a Hold rating on Intercept Pharma (ICPT), with a price target of $54.00. The company’s shares closed last Monday at $52.83, close to its 52-week low of $42.19.
According to TipRanks.com, Olson ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -5.4% and a 41.3% success rate. Olson covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Madrigal Pharmaceuticals, and ACADIA Pharmaceuticals.
Intercept Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $67.67, representing a 35.7% upside. In a report released yesterday, Stifel Nicolaus also maintained a Hold rating on the stock with a $56.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $125.00 and a one-year low of $42.19. Currently, Intercept Pharma has an average volume of 979.5K.
Based on the recent corporate insider activity of 103 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ICPT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
